XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Segments (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 For the three months ended March 31,
(In thousands)20212020
Revenue from services:
Pharmaceutical$— $— 
Diagnostics506,951 170,839 
Corporate— — 
$506,951 $170,839 
Revenue from products:
Pharmaceutical$33,945 $31,074 
Diagnostics— — 
Corporate— — 
$33,945 $31,074 
Revenue from transfer of intellectual property and other:
Pharmaceutical$4,269 $9,553 
Diagnostics— — 
Corporate— — 
$4,269 $9,553 
Operating income (loss):
Pharmaceutical$(19,157)$(14,126)
Diagnostics67,014 (18,133)
Corporate(9,420)(8,503)
$38,437 $(40,762)
Depreciation and amortization:
Pharmaceutical$7,413 $7,121 
Diagnostics12,576 14,871 
Corporate— 60 
$19,989 $22,052 
Loss from investment in investees:
Pharmaceutical$(43)$(134)
Diagnostics— — 
Corporate— — 
$(43)$(134)
Revenues:
United States$512,871 $180,872 
Ireland7,129 11,901 
Chile14,152 10,850 
Spain5,919 4,156 
Israel2,512 1,707 
Mexico2,418 1,841 
Other164 139 
$545,165 $211,466 
(In thousands)March 31,
2021
December 31,
2020
Assets:
Pharmaceutical$1,151,771 $1,176,245 
Diagnostics1,330,183 1,268,738 
Corporate37,621 28,080 
$2,519,575 $2,473,063 
Goodwill:
Pharmaceutical$241,353 $245,793 
Diagnostics434,809 434,809 
Corporate— — 
$676,162 $680,602